Nacuity Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nacuity.com
PK and PD Study of NPI-001 and Cysteamine Bitartrate
Phase 1
Recruiting
- Conditions
- Cystinosis
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nacuity Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05994534
- Locations
- 🇦🇺
Children's Hospital at Westmead, Westmead, New South Wales, Australia
NPI-002 Intravitreal Implant for the Delay of Cataract Progression
Phase 1
Recruiting
- Conditions
- Cataract
- Interventions
- Drug: NPI-002 Intravitreal Implant
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nacuity Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05026632
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
Phase 1
Active, not recruiting
- Conditions
- Usher Syndromes
- Interventions
- Other: PlaceboDrug: NPI-001
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nacuity Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04355689
- Locations
- 🇦🇺
Lions Eye Institute, Perth, Australia
🇦🇺Queensland Eye Institute, Brisbane, Australia
🇦🇺CERA, Melbourne, Australia
© Copyright 2025. All Rights Reserved by MedPath